AVANIR Pharmaceuticals (FRA:AV2B) Return-on-Tangible-Equity : -33.54% (As of Sep. 2014)

AVANIR Pharmaceuticals Return-on-Tangible-Equity Chart

AVANIR Pharmaceuticals Annual Data
	Trend	Sep05	Sep06	Sep07	Sep08	Sep09	Sep10	Sep11	Sep12	Sep13	Sep14
Return-on-Tangible-Equity		Get a 7-Day Free Trial					-116.23	-120.38	-115.25	-266.29	-34.64

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Return-on-Tangible-Equity	Get a 7-Day Free Trial															-691.06	-314.24	-276.49	-108.21	-33.54

Competitive Comparison of AVANIR Pharmaceuticals's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVANIR Pharmaceuticals's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Return-on-Tangible-Equity falls into.

AVANIR Pharmaceuticals Return-on-Tangible-Equity Calculation

AVANIR Pharmaceuticals's annualized Return-on-Tangible-Equity for the fiscal year that ended in Sep. 2014 is calculated as

AVANIR Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2014 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2014) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

AVANIR Pharmaceuticals  (FRA:AV2B) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

AVANIR Pharmaceuticals Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description